| Total subjects n | 491 |
| Anthropometrics | |
| Females/males n | 179/312 |
| Age yrs | 10.8±2.5 |
| Height cm | 144±16 |
| Height z-score | 0.19±1.0 |
| Weight kg | 39±14 |
| Weight z-score | 0.29±0.98 |
| BMI | 18.2±3.1 |
| BMI z-score | 0.25±1.02 |
| IOTF classification | |
| Grade -2 | 2 (0) |
| Grade -1 | 28 (6) |
| Grade 0 | 377 (77) |
| Grade 1 | 76 (15) |
| Grade 2 | 8 (2) |
| History | |
| Birthweight kg# | 3.290±0.515 |
| Atopic dermatitis¶ | 217 (44) |
| Early wheezing¶ | 210 (43) |
| Age at first symptoms (if no early wheezing) yrs | 4 (2.5–6.0) |
| Duration of follow-up months | 40 (19–71) |
| Emergency department visit+ | 158 (44) |
| Parental smoking§ | 98 (20) |
| Atopic statusƒ | |
| Negative | 79 (17) |
| One positive | 109 (24) |
| More than one positive | 267 (59) |
| Treatment | |
| β-agonist on demand | 168 (34) |
| ICS dose## μg·day (n treated; %) | 306±204 (323; 66) |
| LABA | 290 (59) |
| Resting symptoms in the past 3 months | |
| No symptom | 220 (45) |
| Symptom-free days % | 94±10 |
| Severe exacerbation | 64 (13) |
| Exercise complaints | |
| No complaint | 295 (60) |
| Long-distance race | 146 (30) |
| Team play | 50 (10) |
Data are presented as mean±sd, n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; IOTF: International Obesity Task Force; ICS: inhaled corticosteroids; LABA: long-acting β-agonist. #: n=355; ¶: n=489; +: n=359; §: n=491; ƒ: 455 (93%) tested; ##: the dose is given as beclomethasone-equivalent daily dose.